This comprehensive discovery tool includes two siRNAs to each of 139 clinically and scientifically relevant cancer genes
Qiagen introduces the Cancer siRNA Oligo Set, the first set of disease-specific siRNAs for the life sciences market.
This comprehensive discovery tool includes two siRNAs to each of 139 clinically and scientifically relevant cancer genes, chosen in collaboration between Qiagen scientists and leading academic researchers.
Every siRNA has been designed using state-of-the-art design criteria to maximise gene-silencing potential.
The ability to simply, effectively, and specifically down-regulate the expression of genes in mammalian cells holds enormous scientific, commercial, and therapeutic potential.
With the growing acceptance and adoption of siRNA methodologies comes a need for an economical way to study larger numbers of genes.
The Cancer siRNA Oligo Set provides a method by which a large number of cancer-related genes can be studied at once in a cost-effective manner.
All siRNAs in the Cancer siRNA Oligo Set are synthesised using patented TOM-amidite chemistry to yield high-quality, high-purity, 21-nucleotide sense and antisense RNA oligonucleotides.
siRNAs are annealed and purified to >97% purity by HPLC.
